Role of neutrophils in the pathogenesis of nonalcoholic steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) includes a spectrum of liver disorders, from fatty
liver to nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma …
liver to nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma …
[HTML][HTML] Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: A promising drug Potentilla discolor Bunge
L Ji, Q Li, Y He, X Zhang, Z Zhou, Y Gao, M Fang… - … Pharmaceutica Sinica B, 2022 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive accumulation of
hepatic lipids and metabolic stress-induced liver injury. There are currently no approved …
hepatic lipids and metabolic stress-induced liver injury. There are currently no approved …
Exosomal RBP4 potentiated hepatic lipid accumulation and inflammation in high-fat-diet-fed mice by promoting M1 polarization of Kupffer cells
JM Yao, HZ Ying, HH Zhang, FS Qiu, JQ Wu… - Free Radical Biology and …, 2023 - Elsevier
Exosomes containing various biological cargoes have potential to be novel diagnostic
biomarkers for metabolic diseases. In this study, retinol-binding protein 4 (RBP4) was found …
biomarkers for metabolic diseases. In this study, retinol-binding protein 4 (RBP4) was found …
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: novel therapeutic targets
L Yang, Y Hao, J Boeckmans, RM Rodrigues… - Pharmacology & …, 2023 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease
worldwide. Despite extensive research and multiple clinical trials, there are still no FDA …
worldwide. Despite extensive research and multiple clinical trials, there are still no FDA …
Plasma calprotectin levels associate with suspected metabolic-associated fatty liver disease and all-cause mortality in the general population
AR Bourgonje, EH van den Berg, LM Kieneker… - International Journal of …, 2022 - mdpi.com
Metabolic-associated fatty liver disease (MAFLD) is characterized by hepatic steatosis,
metabolic dysregulation, and neutrophilic inflammation. In this study, we hypothesized that …
metabolic dysregulation, and neutrophilic inflammation. In this study, we hypothesized that …
Meeting at the crossroad between obesity and hepatic carcinogenesis: unique pathophysiological pathways raise expectations for innovative therapeutic approaches
The escalating global prevalence of obesity and its intricate association with the
development of hepatocellular carcinoma (HCC) pose a substantial challenge to public …
development of hepatocellular carcinoma (HCC) pose a substantial challenge to public …
CARD9 deficiency aggravated nonalcoholic steatohepatitis in mice through increasing inflammatory response
X Liu, Y Fang, C Qian, J Chen, W Luo, W Zuo… - … et Biophysica Acta (BBA …, 2024 - Elsevier
Nonalcoholic steatohepatitis (NASH), a subtype of nonalcoholic fatty liver disease (NAFLD),
is the leading cause of liver-related morbidity worldwide. Caspase recruitment domain family …
is the leading cause of liver-related morbidity worldwide. Caspase recruitment domain family …
Anti-obesity mechanism of Ganpu tea revealed by microbiome, metabolome and transcriptome analyses
Y Liao, C Wang, Z Gao, Z Pan, M Peng, J Ma, Y Qian… - Food chemistry, 2023 - Elsevier
In this study, the anti-obesity mechanism of Ganpu tea (GPT) from the perspectives of
microbiome, metabolome and transcriptome was investigated. GPT significantly reduced the …
microbiome, metabolome and transcriptome was investigated. GPT significantly reduced the …
Targeting adipose tissue to tackle NASH: SPARCL1 as an emerging player
Nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease, affecting
1.5%–6.5% of the world population. Currently, there are no FDA-approved drugs to treat this …
1.5%–6.5% of the world population. Currently, there are no FDA-approved drugs to treat this …
Hegemony of inflammation in atherosclerosis and coronary artery disease
Inflammation drives coronary artery disease and atherosclerosis implications. Lipoprotein
entry, retention, and oxidative modification cause endothelial damage, triggering innate and …
entry, retention, and oxidative modification cause endothelial damage, triggering innate and …